Cargando…
Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients
OBJECTIVE: Coronavirus disease 2019 (COVID-19) is a systemic disease induced by SARS-CoV-2 causing myocardial injury. To date, there are few data on the correlation between mid-regional proAdrenomedullin (MR-proADM) and myocardial injury. The aim of this study was to evaluate whether the association...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643355/ https://www.ncbi.nlm.nih.gov/pubmed/36388948 http://dx.doi.org/10.3389/fmed.2022.929408 |
_version_ | 1784826506846928896 |
---|---|
author | Spoto, Silvia Mangiacapra, Fabio D’Avanzo, Giorgio Lemme, Daniela Bustos Guillén, César Abbate, Antonio Markley, John Daniel Sambuco, Federica Markley, Roshanak Fogolari, Marta Locorriere, Luciana Lupoi, Domenica Marika Battifoglia, Giulia Costantino, Sebastiano Ciccozzi, Massimo Angeletti, Silvia |
author_facet | Spoto, Silvia Mangiacapra, Fabio D’Avanzo, Giorgio Lemme, Daniela Bustos Guillén, César Abbate, Antonio Markley, John Daniel Sambuco, Federica Markley, Roshanak Fogolari, Marta Locorriere, Luciana Lupoi, Domenica Marika Battifoglia, Giulia Costantino, Sebastiano Ciccozzi, Massimo Angeletti, Silvia |
author_sort | Spoto, Silvia |
collection | PubMed |
description | OBJECTIVE: Coronavirus disease 2019 (COVID-19) is a systemic disease induced by SARS-CoV-2 causing myocardial injury. To date, there are few data on the correlation between mid-regional proAdrenomedullin (MR-proADM) and myocardial injury. The aim of this study was to evaluate whether the association of myocardial injury and elevated mid-regional proAdrenomedullin values could predict mortality of SARS-CoV-2 patients, to offer the best management to COVID-19 patients. MATERIALS AND METHODS: All patients hospitalized for SARS-CoV-2 infection at the COVID-19 Center of the Campus Bio-Medico of Rome University were included between October 2020 and March 2021 and were retrospectively analyzed. Myocardial injury was defined as rising and/or fall of cardiac hs Troponin I values with at least one value above the 99th percentile of the upper reference limit (≥15.6 ng/L in women and ≥34.2 ng/L in men). The primary outcome was 30-day mortality. Secondary outcomes were the comparison of MR-proADM, CRP, ferritin, and PCT as diagnostic and prognostic biomarkers of myocardial injury. Additionally, we analyzed the development of ARDS, the need for ICU transfer, and length of stay (LOS). RESULTS: A total of 161 patients were included in this study. Of these, 58 (36.0%) presented myocardial injury at admission. An MR-proADM value ≥ 1.19 nmol/L was defined as the optimal cut-off to identify patients with myocardial injury (sensitivity 81.0% and specificity 73.5%). A total of 121 patients (75.2%) developed ARDS, which was significantly more frequent among patients with myocardial injury (86.2 vs. 68.9%, p = 0.015). The overall 30-day mortality was 21%. Patients with myocardial injury presented significantly higher mortality compared to those without the same (46.6 vs. 6.8%, p < 0.001). When dividing the entire study population into four groups, based on the presence of myocardial injury and MR-proADM values, those patients with both myocardial injury and MR-proADM ≥ 1.19 nmol/L presented the highest mortality (53.2%, p < 0.001). The combination of myocardial injury and MR-proADM values ≥ 1.19 nmol/L was an independent predictor of death (OR = 7.82, 95% CI = 2.87–21.30; p < 0.001). CONCLUSION: The study is focused on the correlation between myocardial injury and MR-proADM. Myocardial injury induced by SARS-CoV-2 is strongly associated with high MR-proADM values and mortality. |
format | Online Article Text |
id | pubmed-9643355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96433552022-11-15 Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients Spoto, Silvia Mangiacapra, Fabio D’Avanzo, Giorgio Lemme, Daniela Bustos Guillén, César Abbate, Antonio Markley, John Daniel Sambuco, Federica Markley, Roshanak Fogolari, Marta Locorriere, Luciana Lupoi, Domenica Marika Battifoglia, Giulia Costantino, Sebastiano Ciccozzi, Massimo Angeletti, Silvia Front Med (Lausanne) Medicine OBJECTIVE: Coronavirus disease 2019 (COVID-19) is a systemic disease induced by SARS-CoV-2 causing myocardial injury. To date, there are few data on the correlation between mid-regional proAdrenomedullin (MR-proADM) and myocardial injury. The aim of this study was to evaluate whether the association of myocardial injury and elevated mid-regional proAdrenomedullin values could predict mortality of SARS-CoV-2 patients, to offer the best management to COVID-19 patients. MATERIALS AND METHODS: All patients hospitalized for SARS-CoV-2 infection at the COVID-19 Center of the Campus Bio-Medico of Rome University were included between October 2020 and March 2021 and were retrospectively analyzed. Myocardial injury was defined as rising and/or fall of cardiac hs Troponin I values with at least one value above the 99th percentile of the upper reference limit (≥15.6 ng/L in women and ≥34.2 ng/L in men). The primary outcome was 30-day mortality. Secondary outcomes were the comparison of MR-proADM, CRP, ferritin, and PCT as diagnostic and prognostic biomarkers of myocardial injury. Additionally, we analyzed the development of ARDS, the need for ICU transfer, and length of stay (LOS). RESULTS: A total of 161 patients were included in this study. Of these, 58 (36.0%) presented myocardial injury at admission. An MR-proADM value ≥ 1.19 nmol/L was defined as the optimal cut-off to identify patients with myocardial injury (sensitivity 81.0% and specificity 73.5%). A total of 121 patients (75.2%) developed ARDS, which was significantly more frequent among patients with myocardial injury (86.2 vs. 68.9%, p = 0.015). The overall 30-day mortality was 21%. Patients with myocardial injury presented significantly higher mortality compared to those without the same (46.6 vs. 6.8%, p < 0.001). When dividing the entire study population into four groups, based on the presence of myocardial injury and MR-proADM values, those patients with both myocardial injury and MR-proADM ≥ 1.19 nmol/L presented the highest mortality (53.2%, p < 0.001). The combination of myocardial injury and MR-proADM values ≥ 1.19 nmol/L was an independent predictor of death (OR = 7.82, 95% CI = 2.87–21.30; p < 0.001). CONCLUSION: The study is focused on the correlation between myocardial injury and MR-proADM. Myocardial injury induced by SARS-CoV-2 is strongly associated with high MR-proADM values and mortality. Frontiers Media S.A. 2022-10-26 /pmc/articles/PMC9643355/ /pubmed/36388948 http://dx.doi.org/10.3389/fmed.2022.929408 Text en Copyright © 2022 Spoto, Mangiacapra, D’Avanzo, Lemme, Bustos Guillén, Abbate, Markley, Sambuco, Markley, Fogolari, Locorriere, Lupoi, Battifoglia, Costantino, Ciccozzi and Angeletti. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Spoto, Silvia Mangiacapra, Fabio D’Avanzo, Giorgio Lemme, Daniela Bustos Guillén, César Abbate, Antonio Markley, John Daniel Sambuco, Federica Markley, Roshanak Fogolari, Marta Locorriere, Luciana Lupoi, Domenica Marika Battifoglia, Giulia Costantino, Sebastiano Ciccozzi, Massimo Angeletti, Silvia Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients |
title | Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients |
title_full | Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients |
title_fullStr | Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients |
title_full_unstemmed | Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients |
title_short | Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients |
title_sort | synergistic effect of myocardial injury and mid-regional proadrenomedullin elevation in determining clinical outcomes of sars-cov-2 patients |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643355/ https://www.ncbi.nlm.nih.gov/pubmed/36388948 http://dx.doi.org/10.3389/fmed.2022.929408 |
work_keys_str_mv | AT spotosilvia synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT mangiacaprafabio synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT davanzogiorgio synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT lemmedaniela synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT bustosguillencesar synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT abbateantonio synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT markleyjohndaniel synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT sambucofederica synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT markleyroshanak synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT fogolarimarta synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT locorriereluciana synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT lupoidomenicamarika synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT battifogliagiulia synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT costantinosebastiano synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT ciccozzimassimo synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients AT angelettisilvia synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients |